

## **REMARKS**

### **Amendments to the Claims**

With this amendment, claims 1-15, 17-28, and 26-28 are pending. Claims 1 and 26 have been amended. Claims 2-7, 13-15, and 20-25 have been withdrawn as drawn to a non-elected invention. Claim 16 has been canceled without prejudice or disclaimer.

Claims 1 and 26 has been amended to remove reference to non-elected inventions. The claim amendments are made solely in an effort to advance prosecution and are made without prejudice, without intent to acquiesce in any rejection of record, and without intent to abandon any previously claimed subject matter. No new matter has been added by way of these amendments.

### **Restriction Requirement**

With respect to the restriction requirement, Applicants hereby elect with traverse Group V, claims 1, 8-12, 17-19, and 26-28, allegedly drawn to a method of identifying a candidate PTEN pathway modulating agent comprising providing an assay system comprising a MARK nucleic acid comprising SEQ ID NO: 5 with a candidate agent, for prosecution on the merits. Claims 1, 8-12, 17-19, and 26-28 read on the elected invention.

Applicants respectfully request that the amendments be entered. If the Examiner has any questions regarding the amendments and/or response he is directed to contact the Applicant's agent.

Respectfully submitted,

Date: September 23, 2009

/Anita J. Terpstra/  
Anita J. Terpstra  
Registration No. 47,132

McDonnell, Boehnen, Hulbert & Berghoff LLP  
300 S. Wacker Drive  
Chicago, IL 60606  
(312) 913-0001